ImmunityBio (IBRX) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is IBRX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

ImmunityBio, Inc. ( IBRX ) UBS Global Biopharma Conference 2026 November 16, 2026 5:40 AM EST Company Participants Richard Adcock - President, CEO & Director Conference Call Participants Dejia Zhang Presentation Dejia Zh…

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced findings from a national survey of military service members and veterans with non-muscle i…

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced members of the senior leadership team will speak at the upcoming Jefferies Global Healthca…

ImmunityBio's revenues jump 53% on Anktiva adoption, but a wider-than-expected loss, sequential sales decline and rising expenses weigh on shares.…

ImmunityBio's quarterly product sales rose 53% from a year earlier, but they slipped from the prior quarter and missed Wall Street's estimate. Even after Monday's drop, the stock trades at roughly 39 times its annualized…

ImmunityBio Inc. (NASDAQ:IBRX) stock is trading lower on Monday after the company's third-quarter earnings missed expectations.…

ImmunityBio (IBRX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.07 per share a year ago.…

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced continued global expansion, expanded FDA approval, and financial results for the third qua…

JERUSALEM & CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) (“ImmunityBio”) and Rafa Laboratories Ltd. (TASE: RAFA) (“Rafa”) today announced that the Israeli Ministry of Health (MoH) has granted ap…

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.00…

CULVER CITY, Calif. & DUBLIN--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the first patients in Europe received treatment with ANKTIVA® (nogapendekin …

Davidson Kahn Capital Management LLC lessened its stake in ImmunityBio, Inc. (NASDAQ: IBRX) by 50.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm own…

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced completion of the database lock for Cohort A of QUILT-2.005 (NCT02138734), its randomized, controlled, reg…

A recent study published in the Journal of Urology revealed promising long-term results for ImmunityBio, Inc. (NASDAQ:IBRX) and its immunotherapy treatment, ANKTIVA.…

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Jour…

IBRX wins expanded FDA approval for Anktiva plus BCG, covering all patients with BCG-unresponsive NMIBC and broadening its commercial opportunity.…

ImmunityBio Inc. (NASDAQ:IBRX) shares are trading higher Thursday after the FDA expanded the approved indication for its bladder cancer immunotherapy ANKTIVA to include BCG-unresponsive non-muscle-invasive bladder cancer…

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for …

Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and ImmunityBio (NASDAQ: IBRX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the s…

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and Global Chief Scientific …

ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a s…

ImmunityBio Inc. (NASDAQ:IBRX) shares are soaring Friday, extending a steadily rising pattern that's played out over the past several months.…

State Street Corp raised its position in ImmunityBio, Inc. (NASDAQ: IBRX) by 20.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund own…

ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.…
Kept in their own lane. A press release is the company talking, not reporting.

